Michael Przybylski
Papers
1
Total Citations
11
H-Index
1
About
Michael Przybylski is a leading figure in bioanalytical chemistry and clinical proteomics, with a primary focus on developing innovative mass spectrometry-based diagnostic tools for lysosomal storage diseases (LSDs). His major contributions center on advancing chip-based nanoelectrospray ionization mass spectrometry for rapid, high-throughput clinical screening. Notably, his 2013 work demonstrated the feasibility of fully automated chip-based nanoESI-MS as a novel method for diagnosing Fabry disease, a severe LSD caused by α-galactosidase A deficiency. By enabling direct enzyme activity measurement from dried blood spots, this approach significantly reduces diagnostic time and complexity compared to traditional methods. With over a decade of impact, his highly cited paper (11 citations) has paved the way for newborn screening and early intervention strategies. Przybylski’s work exemplifies the translation of cutting-edge analytical chemistry into practical clinical solutions, offering hope for earlier detection and management of devastating genetic disorders. His research continues to inspire advances in precision diagnostics and biomarker discovery.
Research Focus
Key Achievements
Top Papers
- 1